#4663 BLOOD AND URINARY CYTOKINE PROFILES AND CLINICAL OUTCOME IN PRIMARY MEMBRANOUS NEPHROPATHY AND DIABETIC KIDNEY DISEASES

Abstract Background and Aims Primary membranous nephropathy (MN) is an autoimmune, immune complex-mediated primary glomerulopathy causing podocyte injury nephrotic syndrome. The results of therapy may be suboptimal biomarkers are needed that predict the need for suppression response to different immunosuppression regimens. Diabetic kidney disease (DKD) most common cause failure. It characterized by non-immune lead We evaluated circulating urine cytokine pattern pathophysiologic difference between both conditions. For MN, we further aimed at identifying immunosuppressive treatment response. Method 192 MN data-points from STARMEN trial 92 DKD biobank IIS-FJD-UAM were included. analyzed blood samples HISCL (Sysmex Inc. Kobe, Japan), a chemiluminescence immunoassay can afford high-throughput multiplex analysis. Sixteen measured correlation with clinical outcome (eGFR, uPCR, 24-hour proteinuria). Also, biomarkers’ concentration baseline was compared during 6-9 months status after until 24 months. treatments Tacrolimus-Rituximab (TacRt) alternating corticosteroids-cyclophosphamide. Box plot Mann Whitney U test used assess subgroup differences Spearman's rank variables. Results Median age, eGFR proteinuria cohorts 53 66 years, 74 52 ml/min/1.73 m2, 8.8 0.2 g/24h, respectively. Five markers in 5 2 showed significant (Table). Circulating TNFa had been previously related pathophysiology confirmed its outcomes both. CCL20 one correlated anti-PLA2R (rS = 0.151, p 0.036) but not DKD. identified urinary Protein A whose differed responders non-responders TacRt. Conclusion displayed characteristic patterns. progression chronic inflammation B cells. Its presence TacRt suggest high inflammatory activities offset In conclusion, protein could potential prognostic marker However, additional investigation confirm evaluate possible application other glomerular diseases.